Infectious Disease CRISPR Market Report Scope & Overview:

The Infectious Disease CRISPR Market was valued at USD 310.00 Million in 2025 and is expected to reach USD 1.90 Billion by 2035, growing at a CAGR of 19.90% from 2026-2035.

The Infectious Disease CRISPR Market will grow, due to the rising burden of infectious disease cases around the world, owing to advancements in CRISPR-Cas technology and increased investments in biotechnology and genomics. The use of CRISPR/Cas12- and CRISPR/Cas13-based diagnostic methods for the rapid, precise, and inexpensive detection of bacteria and viruses is being made possible through platforms like DETECTR and SHERLOCK. With more funds being made available by governments, institutions, and philanthropies in the research of CRISPR-based tests and treatment options for HIV, tuberculosis, HPV, and influenza, pharmaceutical companies, biotech companies, and academic institutions are improving the efficiency of assays. However, regulatory issues, ethics issues, and challenges of using gene editing will impact market growth around the world.

In June 2024, researchers at the Broad Institute and Princeton University developed an affordable, rapid CRISPR-based paper strip test to distinguish influenza A and B, including H1N1 and H3N2 subtypes. The innovation supports faster, accessible point-of-care diagnosis, reducing reliance on laboratory processing and enabling more targeted influenza treatment.

Infectious Disease CRISPR Market Trends

• CRISPR/Cas12 DETECTR and Cas13 SHERLOCK platforms enable point-of-care diagnostics for bacterial and viral infections.

• Government and philanthropic funding increasingly supports CRISPR diagnostics targeting HIV, tuberculosis, and HPV across emerging markets.

• CRISPR-Cas3 modified bacteriophage therapeutics are progressing through clinical trials targeting antimicrobial-resistant bacterial infections.

• Portable, instrument-free molecular diagnostic kits are expanding CRISPR infectious disease testing across remote, underserved regions.

• Academic and government institutes increasingly secure dedicated grants for CRISPR tools supporting pandemic preparedness and response.

• Paper strip and lateral flow CRISPR diagnostics reduce testing costs while distinguishing closely related viral subtypes.

U.S. Infectious Disease CRISPR Market Outlook

The U.S. Infectious Disease CRISPR Market was valued at USD 109.58 Million in 2025 and is expected to reach USD 0.61 Billion by 2035, growing at a CAGR of 18.71% from 2026-2035.

The U.S. Infectious Disease CRISPR Market for diagnosis and therapy is still fueled by an excellent research and development environment, increased incidences of infections, and constant government funding to develop CRISPR technologies. There are ongoing efforts by research organizations all over the country to develop new CRISPR technology for POC screening and gene editing treatment of HIV, tuberculosis, and other infections with support from various funding bodies such as the National Institutes of Health among others. With so many CRISPR pioneers and research hospitals in the country, there is rapid transition from laboratory innovation to clinical applications.

In June 2024, University of Florida researchers received approximately USD 2.8 million from the National Institutes of Health to develop a CRISPR-based HIV home detection kit. The device uses microfluidic technology to measure HIV RNA levels, delivering results within minutes and potentially expanding rapid infectious disease testing beyond traditional clinical settings.

Infectious Disease CRISPR Market Segment Analysis

• By Application, the Diagnostics segment dominated the Infectious Disease CRISPR Market with approximately 58.40% share in 2025, while the Therapeutics segment is the fastest growing with a CAGR of approximately 22.85%.

• By Product, the Kits and Reagents segment dominated the Infectious Disease CRISPR Market with approximately 42.60% share in 2025, while the Guide RNA segment is the fastest growing with a CAGR of approximately 23.10%.

• By End-User, the Pharmaceutical Companies and Biotechnology Companies segment dominated the Infectious Disease CRISPR Market with approximately 56.90% share in 2025, while the Academics and Government Research Institutes segment is the fastest growing with a CAGR of approximately 21.40%.

By Application, Diagnostics Dominates and Therapeutics Grows Fastest

The diagnostic applications based on CRISPR dominate 2025 due to their precision, rapidity, and the possibility of detecting specific genetic sequences associated with the diagnosis of infectious diseases that arise from viruses, bacteria, and other pathogens. The DETECTR and SHERLOCK methods have demonstrated the same level of sensitivity as the PCR tests but without requiring pre-amplification, thus being especially relevant for point-of-care solutions and confirming diagnostics as the default choice for CRISPR implementation within the management of infectious diseases.

Therapeutics are developing at the highest rate currently, and there is ongoing clinical testing of CRISPR-Cas3 phage therapy and CRISPR/Cas9-based gene editing in order to treat antimicrobial resistance and chronic viral reservoirs like HIV. The development of the therapeutic sector relies greatly on clinical proof of safety and biodistribution in humans, which can increase credibility and make gene editing another promising growth driver along with the diagnostics field.

By Product, Kits and Reagents Dominates and Guide RNA Grows Fastest

Kits and reagents dominate the market in 2025, reflecting their essential role in every CRISPR-based diagnostic workflow, from sample preparation through detection and reporting. Their recurring, per-test consumption pattern and compatibility with a wide range of point-of-care and laboratory-based platforms continue to anchor this segment's leading revenue contribution across both diagnostic and research applications.

Guide RNAs are growing faster due to an increasing requirement for tailored guide sequences for the therapy of certain diseases, as they can accurately identify certain regions of the genome of the virus or bacteria. Guide RNA technology is further benefited by the developments in computational technologies used in the design of guide RNAs.

By End-User, Pharmaceutical Companies and Biotechnology Companies Dominate and Academics and Government Research Institutes Grow Fastest

Pharmaceutical and biotechnology companies dominated the market in 2025, accounting for the largest share of demand and reflecting their central role in commercializing CRISPR-based diagnostic kits and advancing therapeutic candidates through clinical development. These companies benefit from established regulatory relationships, manufacturing scale, and distribution networks that position them to translate early-stage CRISPR innovations into approved, widely available products.

Academic and government research institutes are growing fastest as dedicated federal and philanthropic funding increasingly flows toward CRISPR-based infectious disease research aimed at pandemic preparedness and underserved disease areas. This segment benefits from grant-funded programs at universities and public health institutes that are developing next-generation sequencing and CRISPR gene-editing methods to create more targeted, accurate, and user-friendly point-of-care diagnostic tests.

Regional Analysis

North America Infectious Disease CRISPR Market Insights

North America accounted for approximately 41.20% of the global Infectious Disease CRISPR Market in 2025, the largest share of any region, fueled by technological advancements, rising incidence of infectious diseases, and the region's emphasis on innovative research with strong funding support. The United States drives the substantial majority of regional demand, supported by leading academic institutions advancing novel CRISPR-Cas-based diagnostic platforms for oral pathogens, HPV, HIV, and other infectious agents.

Canada is advancing through substantial federal research investment, exemplified by researchers at the University of Alberta securing nearly USD 75 million in new federal research grants to help the country prepare for future infectious disease pandemics through vaccines, diagnostic tests, and CRISPR-based treatments. Mexico contributes a smaller but steadily growing share of regional revenue as domestic biotechnology research capacity gradually expands.

Europe Infectious Disease CRISPR Market Insights

The European continent still makes up a prominent regional market, where Germany, the UK, and France make up the leading contributions from the national perspective. The demand is underpinned by the presence of advanced academic research networks, health care system diagnostics screening programs, and rising investments in biotechnologies aimed at developing CRISPR-based technologies to treat infectious diseases.

Germany takes the leadership of the regional market with its advanced biotechnological research activities and developed network of pharmaceutical production facilities. At the same time, the UK and France still keep on widening academic and medical research cooperation with the purpose to develop CRISPR-based diagnostics for TB, HIV, and other viruses. Italy and Spain make up the secondary regional markets due to the expansion of research funding to the second-level biotechnological centers.

Asia Pacific Infectious Disease CRISPR Market Insights

Asia Pacific is the fastest-growing regional market, projected to expand at a CAGR of approximately 23.65% between 2026 and 2035, driven by rising infectious disease burden and expanding biotechnology research infrastructure across China, Japan, and India. China represents a leading national market within the region, supported by rapid growth in domestic genomics research capacity and CRISPR technology development.

The Indian Council of Medical Research has been able to devise an affordable and portable CRISPR test for Tuberculosis in India. The technique involves the use of the sputum of the patient and is comprised of three easy-to-perform steps, reflecting the capability of the region to come up with affordable tests. Japan, Australia, and South Korea are some technologically-advanced countries in the region.

MEA & Latin America Infectious Disease CRISPR Market Insights

The Middle East & Africa region is led by the GCC countries, where government healthcare investment programs are gradually increasing emphasis on advanced diagnostic technologies, including CRISPR-based infectious disease testing, within newly commissioned research and clinical facilities. South Africa represents the largest contributor within the African portion of the region, supported by a comparatively developed biomedical research base addressing the region's significant infectious disease burden, while broader regional adoption remains constrained by limited local biosafety and genomics research infrastructure.

Latin America is led by Brazil, which accounts for the largest share of regional revenue on the strength of its expanding biotechnology research sector and growing public health investment in infectious disease diagnostics. Argentina represents the second-largest national market, supported by academic research collaborations, while growth across the rest of the region is gradually accelerating as national health ministries prioritize modernization of infectious disease testing infrastructure.

Market Dynamics

Growth Drivers: Rising Infectious Disease Burden and CRISPR Technology Advancement

Infectious Disease CRISPR Market Growth is mainly attributed to the increase in cases of infectious diseases such as influenza, cholera, and HIV across the world, which has resulted in the increased need for efficient and accurate diagnosis and treatment tools. Progress in the CRISPR-Cas system, which includes enhanced accuracy and efficiency in the Cas12- and Cas13-based systems, is contributing to the wider use of CRISPR technology for diagnoses of bacterial and viral infections.

The increase in funding by the government and non-governmental organizations towards biotechnological research, as well as the development of CRISPR technologies, is driving the market growth. In addition, studies being carried out in organizations that develop CRISPR technologies for combating pandemics and antimicrobial resistance are widening the scope of the application of the technology from diagnostics to gene editing therapy.

Restraints: Ethical Concerns and Regulatory Challenges

Ethical concerns surrounding gene-editing technologies, particularly as CRISPR applications extend from diagnostics into human therapeutics, continue to warrant careful scientific and public scrutiny. Regulatory frameworks governing CRISPR-based diagnostic and therapeutic products remain in active development across many jurisdictions, creating uncertainty for developers navigating approval pathways for novel gene-editing interventions targeting infectious diseases.

The need for rigorous clinical validation of safety, biodistribution, and off-target effects for CRISPR-based therapeutics adds substantial time and cost to product development, particularly for gene-editing approaches targeting chronic viral reservoirs such as HIV. These regulatory and ethical considerations may moderate the pace of therapeutic adoption even as diagnostic applications continue to advance more rapidly through established regulatory pathways.

Opportunities: Point-of-Care Diagnostics and Government-Funded Research

There is huge potential in the evolution of CRISPR diagnostic technologies that do not require any instruments at the point of care. Such affordable and portable diagnostic systems would allow conducting screenings for infectious diseases in underserved and hard-to-reach locations with no laboratory facilities. Companies capable of integrating CRISPR-based diagnostics with lateral flow strip tests have an excellent chance to capitalize on the need.

Growing government and philanthropic funding for CRISPR-based infectious disease research, exemplified by substantial grants supporting pandemic preparedness and gene-editing therapeutics for HIV and tuberculosis, is opening substantial opportunities for research institutions and technology developers. Expanding biotechnology research infrastructure across Asia Pacific, the Middle East, and Latin America offers manufacturers a durable runway for geographic expansion beyond mature North American and European markets.

Recent Developments:

• 2024, Locus Biosciences presented positive Phase 1/2 ELIMINATE trial findings for LBP-EC01, demonstrating effective dosing, good tolerance, and high drug concentrations at infection sites.

• 2024, Excision BioTherapeutics’ EBT-101 Phase 1/2 trial achieved its primary safety endpoint and secondary biodistribution and immunogenicity endpoints, supporting safe CRISPR-based targeting of HIV DNA reservoirs.

• 2023, Sherlock Biosciences received additional funding from the Bill & Melinda Gates Foundation to advance rapid, instrument-free CRISPR molecular diagnostics for Human Papillomavirus in underserved communities.

• 2024, the Indian Council of Medical Research developed a cost-effective, portable CRISPR-based tuberculosis detection system using sputum samples, aiming to expand affordable screening access across resource-constrained settings.

• 2024, Washington University School of Medicine researchers received a USD 6.2 million NIH grant to develop CRISPR-enabled gene therapy enhancing B-cell production of broadly neutralizing HIV antibodies.

Infectious Disease CRISPR Market Key Players

• Mammoth Biosciences, Inc.

• Sherlock Biosciences (OraSure Technologies)

• Caribou Biosciences, Inc.

• Editas Medicine

• Intellia Therapeutics, Inc.

• CRISPR Therapeutics

• Beam Therapeutics

• Horizon Discovery Ltd

• Synthego

• Thermo Fisher Scientific Inc.

• Merck KGaA

• GenScript

• Cepheid (Danaher)

• Abbott Laboratories

• QIAGEN N.V.

• Bio-Rad Laboratories, Inc.

• Agilent Technologies, Inc.

• Integrated DNA Technologies, Inc.

• New England Biolabs, Inc.

• Twist Bioscience Corporation

Infectious Disease CRISPR Market Report Scope: